PTC Therapeutics Inc PTCT

NAS: PTCT | ISIN: US69366J2006   10/12/2025
74,10 USD (+0,86%)
(+0,86%)   10/12/2025

1 december 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 november 2025 · PTC Therapeutics to Host R&D Day · Persbericht

4 november 2025 · PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results · Persbericht

31 oktober 2025 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

27 oktober 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 oktober 2025 · PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results · Persbericht

1 oktober 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 augustus 2025 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

19 augustus 2025 · PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA · Persbericht

7 augustus 2025 · PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results · Persbericht

28 juli 2025 · PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) · Persbericht

21 juli 2025 · PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results · Persbericht

24 juni 2025 · PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm · Persbericht

23 juni 2025 · Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) · Persbericht

19 juni 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 mei 2025 · PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results · Persbericht

5 mei 2025 · PTC518 PIVOT-HD Study Achieves Primary Endpoint · Persbericht

1 mei 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

25 april 2025 · PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) · Persbericht

24 april 2025 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

Mijn selecties